Register for our free email digests:
Amarin Corp. PLC
www.amarincorp.com
Latest From Amarin Corp. PLC
Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster
Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.
Amarin CEO Thero On Gearing Up For Success Ahead Of The Big Vascepa Ad Comm
"We're planning for success," John Thero told Scrip in an interview, where he talked about the upcoming US advisory committee meeting for Vascepa, commercial expansion plans and deflected questions about a big pharma buyout.
Vascepa Advisory Committee Is Latest Outpost In Product's Remarkable Regulatory Journey
The last time representatives from Amarin and US FDA formally met in public, it was in court.
Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'
As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Alias(es)
- Ethical Holdings
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Ireland
-
Ireland
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Amarin Corp. PLC
- Senior Management
-
John F Thero, Pres. & CEO
Michael W Kalb, SVP, CFO
Craig B Granowitz, MD, PhD, SVP, CMO
Rami Daoud, SVP, Corp. Dev.
Steven Ketchum, PhD, SVP, R&D & CSO
Aaron Berg, SVP, Chief Commercial Officer - Contact Info
-
Amarin Corp. PLC
Phone: (353) 1 6699 020
2 Pembroke House, St. 28-32
Dublin 2,
Ireland
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice